The Current Field of Graft Versus Host Disease

Robert Zeiser, MD, reviews the pathophysiology of graft versus host disease and explains its relationship to the desired graft versus leukemia effect.

Dr Zeiser outlines the differences between acute and chronic GVHD and also reviews factors that put transplant patients at greater risk of GVHD.

Selection of prophylaxis regimen is reviewed followed by a discussion of the typical patient presentation of GVHD.

A GVHD expert comments on the frontline therapy available for the condition.

Therapies for steroid-refractory chronic graft-vs-host disease, ibrutinib, ruxolitinib, and belumosudil, are explored in a comprehensive analysis.

Robert Zeiser, MD, touches on additional therapeutic options for steroid-refractory chronic graft-vs-host-disease, such as extracorporeal photopheresis, mycophenolate, everolimus, and more.

Adverse events related to chronic graft-vs-host-disease therapies and strategies to manage these adverse effects are considered.

Closing out the program, Robert Zeiser, MD, shares what he is looking forward to in the field of graft-vs-host-disease.